Table 1.
Baseline Demographic Data and Disease Characteristics from a Phase III Study of Abarelix Depot Versus Leuprolide Depot for the Treatment of Prostate Cancer
| Leuprolide Depot | Abarelix Depot | |
|---|---|---|
| (n = 89) | (n = 180) | |
| Race (%) | ||
| Caucasian | 82 | 88 |
| African American | 9 | 6 |
| Hispanic | 7 | 3 |
| Asian | 2 | 3 |
| Median age (y) | 74 | 73 |
| Median weight (lb) | 184 | 190 |
| Body mass index (kg/m2) | 27.4 | 27.5 |
| Reason for treatment (%) | ||
| D1/D2 stage | 8 | 8 |
| Rising PSA | 33 | 37 |
| NHT | 36 | 37 |
| IHT | 24 | 17 |
| None of the above | 0 | 1 |
| Baseline PSA (ng/mL) (%) | ||
| 0–<4 | 17 | 17 |
| 4–<10 | 36 | 33 |
| 10–20 | 22 | 21 |
| >20 | 24 | 26 |
| Unknown | 1 | 4 |
PSA, prostate-specific antigen; NHT, neoadjuvant hormone therapy; IHT, intermittent hormone therapy.